Baxter completes vaccine biz sale to Pfizer; GI Dynamics resumes EU shipments;

@FierceMedDev: ICYMI: U.K. and Wellcome Trust back trial of new, 15-minute Ebola test in West Africa. FierceDiagnostics article | Follow @FierceMedDev

@EmilyWFierce: Merck KGaA will hold onto its consumer health biz--for now. FiercePharma story | Follow @EmilyWFierce

> Pfizer ($PFE) acquired Baxter's ($BAX) vaccine portfolio and manufacturing facility in Orth, Austria. Baxter is in the midst of refocusing its business on medical products and is spinning out its biopharma business. Release

> U.S. Supreme Court Justice Ruth Bader Ginsburg received a stent implant in a coronary artery and is recovering smoothly. News

> GI Dynamics, maker of Type 2 diabetes treatment device EndoBarrier, received permission from the EU to resume selling the device. The company has agreed to clarify the indicated population on its label as specifically for obese Type 2 diabetics or patients with other comorbidities with a BMI of ≥ 30 kg/m2 or obese patients with a BMI of ≥ 35 kg/m2. Release

> Ireland-based startup PMD Solutions has developed a patient breathing monitor and patch system, RespiraSense, which has received a CE mark and is slated to launch. Story

Biotech News

@FierceBiotech: After numerous setbacks, $LLY mounts another pivotal assault on Alzheimer's. More | Follow @FierceBiotech

@JohnCFierce: Takeda gets a BTD designation on ixazomib (MLN9708), for the treatment of relapsed or refractory systemic light-chain (AL) amyloidosis. FierceBiotech story | Follow @JohnCFierce

@DamianFierce: In which hackers trick bankers into tipping them off to biopharma buyouts. Story | Follow @DamianFierce

> Fresh from a $3.85B deal, biotech CEO sets sights on the next big thing. Story

> Top research institutions hand hot gene-editing tech--with a catch--to Editas. More

> Buzz: Deep job cuts looming at GlaxoSmithKline's U.S. ops in RTP, Philly. Article

> As PDUFA looms Sanofi punts a $35M partnership. Item

Pharma News

@FiercePharma: Zoetis R&D chief Catherine Knupp on the fight to stay atop animal health. FierceAnimalHealth article | Follow @FiercePharma

@CarlyHFierce: UPDATED with a statement from $NVS - Novartis flu vaccine under the lens as Italy probes 13 deaths. Article | Follow @CarlyHFierce

> Reuters: In Fresenius, Danone could lose second suitor for nutrition unit. Item

> GSK ready to ax hundreds in U.S., sources tell Bloomberg. Story

> Novartis flu vaccine under the lens as Italy probes 13 deaths. Article

> Merck KGaA will hold onto its consumer health biz--for now. Report

CRO News

> Almac partners up to keep patients--and data--safe in trial emergencies. More

> WuXi pairs up with deCODE spinout to further its genomics expansion. News

> GVK gets its drug repurposing tech into Japan with new partnership. Story

> Quintiles pools postmarketing services into a single offering. Item

> Accovion reaches into France amid expansion kick. Article

Biotech IT News

> U.K. heavyweights commit $16M to Oxford Uni genome data analysis spinout. Report

> Texas' $3B cancer agency makes computational biology a priority. News

> Nvidia backs projects to tap GPUs for cancer research. Story

> Humana agrees to contribute information to PearlDiver's database. Article

> Monocl Software bags grant for KOL assessment platform. More

Animal Health News

> Bayer launches smartphone app to help farmers monitor dairy herd health. Story

> Natura Pet issues 8-state voluntary recall of cat food; Canada included. More

> IDEXX aids in discovery of new biomarker to spot early kidney disease in cats. Item

> Dutch set safety corridor as a bird flu hits a fourth poultry farm. News

> Nova Scotia establishes program to support beef industry and safety standards. Article

Suggested Articles

The FDA has cleared its first fully disposable duodenoscope, following years of reports of infections being transmitted between patients.

OR-focused AI provider Caresyntax has garnered $45.6 million in new funding and picked up a data analytics firm to broaden its footprint.

A study of Foundation Medicine’s FoundationOne liquid biopsy test found it was able to predict the risk that a person’s breast cancer would return.